AI Longevity Daily

Today’s Summary

Nearly half of low-risk adults have coronary artery inflammation missed by routine blood tests — only cardiac CT can catch it.
Getting less than 42 minutes of bright sunlight daily is linked to higher dementia risk more strongly than six known risk factors in an observational study.
The coronary inflammation study comes from an in-house investigation with undisclosed sample composition, and there's no evidence yet that intervention reduces heart attacks.

💡 Today’s Top 10 Focus

1. Hearts That Look Healthy? 42.9% Have Arterial Inflammation — and Blood Tests Miss It All

Biograph, a preventive health company, released an in-house study : they ran AI analysis on coronary CT scans (a routine cardiac imaging method) to measure inflammation in tissues surrounding arteries, focusing on asymptomatic adults classified as “low-risk” by traditional risk assessment. The results? 42.9% showed elevated inflammation, with 17.9% having extremely high inflammation around at least one major coronary artery. Even more striking — about 47% of those with elevated inflammation had zero visible plaque on their CT scans. The cholesterol markers, blood sugar, general inflammation markers (hs-CRP, a blood indicator of systemic inflammation), and the American Heart Association risk assessment model used for comparison all failed to flag these folks. All participants were members of the same clinic, the announcement didn’t disclose total numbers, and the organization is both researcher and testing service provider. Perivascular inflammation is a warning signal, but there’s currently no evidence that intervening on it actually reduces heart attacks. 💔

2. Less Than 42 Minutes of Sunlight a Day? The Dementia Link Is Stronger Than Six Known Risk Factors

An observational study packing in over 87,000 adults found that getting more bright light exposure during the day was associated with a 16% lower dementia risk. But here’s the kicker: getting less than 42 minutes of bright sunlight daily had a stronger predictive association with dementia than six established dementia risk factors, according to Science Daily’s coverage . This is a correlational study, so it can’t prove that sunlight itself prevents dementia. Specific sample composition, follow-up duration, and journal info still need to be checked against the original paper. ☀️

3. Study of Nearly 13,000 People: High Artificial Sweetener Intake Linked to Accelerated Memory Decline

Artificial sweeteners are the story here. An analysis of nearly 13,000 adults found that people consuming the most artificial sweeteners experienced memory and thinking decline about 62% faster than those consuming the least — that’s equivalent to an extra 1.6 years of aging, according to Science Daily’s coverage . All six common sweeteners tested were linked to accelerated cognitive decline. Researchers explicitly noted this is correlational and no causal relationship was established; journal source and detailed methods still need to be verified from the original paper. 🧠

4. Monkey Study: Combo Drug Makes 93% of Weight Lost Come From Fat, Not Muscle

Semaglutide (a GLP-1 receptor agonist that mimics gut hormones to curb appetite for weight loss) has caught flak because a solid chunk of the weight people lose is muscle, not just fat. iBio tackled this in an 8-week non-human primate study with its experimental antibody IBIO-610: monkeys on semaglutide alone lost weight that was 77% fat, but adding a single dose of IBIO-610 bumped that ratio up to 93%, according to Longevity.Technology’s coverage . Each group had only 6 animals over just 8 weeks — a tiny sample; the announcement didn’t compare total weight loss between groups. A first-in-human safety trial is planned for the first half of 2027, and whether animal results translate to humans remains an open question. 🐒

5. Brain Aging Speeding Up or Slowing Down? Older Brains Handle Sleep Loss Better Than Younger Ones

Simon Fraser University dropped a new study suggesting that healthy older adults’ brains may decline less than younger folks’ when sleep-deprived, according to MedicalXpress’s coverage . Specific experimental design, participant numbers, and measurement methods still need to be verified from the original paper; whether this generalizes to older adults with chronic conditions or sleep disorders remains unclear. 😴

6. First Whole-Body Single-Cell Atlas of an Adult Vertebrate — Built in a Tiny Transparent Fish

Whitehead Institute researchers pulled off a first: they sequenced over 600,000 cells from Danionella cerebrum — a transparent fish barely 12 mm long — to build the first complete whole-body single-cell atlas of an adult vertebrate, published in Science . A single-cell transcriptome atlas records which genes each cell is actively using — essentially a “work snapshot” of every cell across the entire animal. The atlas revealed how forebrain neurons sequentially go through immune response, stem cell activation, and new neuron maturation after injury. This dataset is now publicly available through the interactive database DigiFish, giving brain regeneration and aging researchers a searchable reference map. The study organism is a fish, though, so whether these mechanisms can be directly extrapolated to the human brain still needs targeted validation. 🐟

7. Why Is Stem Cell Therapy So Hit-or-Miss? Cell Senescence During In Vitro Expansion May Be the Culprit

Fight Aging! highlighted an open-access paper tackling a hidden problem affecting stem cell therapy quality: cells may largely enter a senescent state during in vitro culture expansion (senescent cells lose their ability to divide but keep pumping out pro-inflammatory signals), which then compromises the quality of cells injected into patients. The paper specifically noted that neural stem cells, when senescent, accumulate toxic proteins in their secretions that could trigger chain-reaction secondary senescence in recipient cells. The authors recommend baking senescence-level testing and extracellular vesicle proteomics analysis into stem cell production standards, but clinical feasibility and scaling pathways need more work. 🔬

8. FDA Greenlights Soft Mist Inhaler Trial Targeting COPD With Pulmonary Hypertension

United Therapeutics got the FDA’s go-ahead to run a Phase II safety trial of a treprostinil soft mist inhaler in about 40 patients, targeting COPD combined with pulmonary hypertension (PH-COPD) — a serious complication involving high blood pressure in the lungs, according to Longevity.Technology’s coverage . The company estimates 400,000 to 800,000 Americans have both conditions, but this complication has long flown under the radar because its symptoms heavily overlap with COPD, and there are currently no approved treatments. The 16-week double-blind trial’s primary goal is safety and tolerability — it can’t prove efficacy yet. If things go smoothly, a Phase III trial is expected to kick off in 2028. 💨

9. Klotho Protein Sustained Delivery: Cell Capsule Tech Validates Long-Term Secretion In Vitro

Avaí Bio announced a peer-reviewed article in Frontiers in Aging, reporting that Klothonova — its joint platform with Austrianova — successfully achieved long-term production and secretion of Klotho protein in vitro, according to Longevity.Technology’s coverage . Klotho is a protein that declines with age and is closely tied to kidney, cardiovascular, and neurodegenerative diseases. The Cell-in-a-Box technology encapsulates living cells in porous capsules that let nutrients and proteins in and out while blocking immune system attacks. So far the results are only from in vitro experiments — optimal dosing, long-term safety, and clinical efficacy all need more research. 🧬

10. Voyager to Showcase Early Data on Two Tau-Targeted Therapies at Alzheimer’s Conference

Voyager Therapeutics announced it will present two studies at the Alzheimer’s Clinical Trials Conference (CTAD 2026) on November 16–19, according to Longevity.Technology’s coverage . VY1706 is a gene therapy designed to reduce tau protein production in the brain (abnormal tau buildup is a core pathology of Alzheimer’s), and the presentation will cover its first-in-human study design. VY7523 is a monoclonal antibody targeting a specific region of the tau protein, and it will report baseline characteristics from a multiple-ascending-dose study. Both are in early exploratory stages — what’s being shown this time is study design and baseline data, not efficacy results. 🎯

🚀 Product & Feature Updates

Health Platforms Can Now Tap 1,000+ Imaging Facilities Through a Single API

Fitnescity Health announced API integration is now open : any health platform can plug into a single interface and offer users booking access at over 1,000 locations across the US, including DEXA scans (low-dose X-rays to estimate fat, muscle, and bone density ratios), cardiac coronary calcium scoring CT (for cardiovascular risk assessment), and VO2 Max testing (measuring aerobic metabolism capacity). Ten platforms including Superpower have already jumped on board — users can pick a location, book, and view results right in the app. Booking compliance, physician oversight, and report extraction are all handled by Fitnescity. The report didn’t touch on scan costs or result interpretation standards, and whether routine imaging for asymptomatic people does more good than harm is still up for debate — worth keeping in mind as you dig deeper. 🏥

🔬 Frontier Research

Cancer Survivors’ Diet and Heart Disease Risk: Observational Study Published in JACC: Advances

A study published in the cardiology journal JACC: Advances reports that among cancer survivors, healthier dietary patterns are associated with lower heart disease incidence and mortality, according to MedicalXpress’s coverage . Cancer survivors typically face elevated cardiovascular risk due to treatment side effects, making dietary intervention research in this population practically meaningful. Specific participant numbers, follow-up duration, and dietary assessment methods still need to be verified from the original paper; observational studies can’t rule out the influence of other lifestyle factors. 🥗

📊 Industry Changes & Personal Impact

Longevity Biotech Market Projected to Top $31 Billion by 2030 — But Market Concentration Is Almost Zero

The Business Research Company released a forecast report estimating that the longevity biotech market will exceed $31 billion by 2030, with a compound annual growth rate of about 8%. Preventive health programs are expected to claim the largest share (about 41% of a larger ~$41 billion market), with biological age testing contributing roughly $5 billion. Notably, the report also points out that this market is wildly fragmented — the top 10 companies combined account for only about 0.3% of 2025 revenue, meaning there’s no dominant player yet. Market forecasts are based on growth assumptions rather than realized earnings, so treat the numbers as trend indicators rather than certainties; clinical efficacy evidence for longevity biotech still lags behind the market hype. 📈